Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.9
3.3
Journals
Brain Sciences
Special Issues
Progression of Cognitive Decline in Older Adults with Parkinson’s
share announcement

Progression of Cognitive Decline in Older Adults with Parkinson’s

A special issue of Brain Sciences (ISSN 2076-3425).

Deadline for manuscript submissions: closed (23 December 2019) | Viewed by 10286

Special Issue Editors

Dr. Alison Yarnall

E-Mail Website
Guest Editor
Newcastle University, Instution of Neuroscience, Brain And Movement Research Group, Newcastle Upon Tyne, Tyne and Wear, NE4 5PL, UK
Interests: Parkinson’s disease; cognition; neurodegeneration; mild cognitive impairment; dementia; ageing; falls; gait; cholinergic function
Dr. Rachael Lawson

E-Mail Website
Guest Editor
Newcastle University, Instution of Neuroscience, Brain And Movement Research Group, Newcastle Upon Tyne, Tyne and Wear NE4 5PL, UK
Interests: Parkinson’s disease; cognition; neurodegeneration; dementia; mild cognitive impairment; neuropsychology; neuropsychiatry; quality of life

Special Issue Information

Dear Colleagues,

The prevalence of Parkinson’s disease, and thus the burden of the associated non-motor symptoms will increase in future years, because of the secular trends in the age-structure of populations. The rising age in the general population often equates to an increase in co-morbidities and associated polypharmacy. Therefore, the detection and, if possible, prevention, of cognitive impairment associated with Parkinson’s disease is of the upmost importance for future generations, in terms of healthcare costs, social care, and the prevention of morbidity and mortality. Parkinson’s disease dementia is common and is associated with increased mortality, morbidity, care home admission, and with a poorer quality of life. As both Parkinson’s disease and Parkinson’s disease dementia are more common in older adults, the focus of cognitive decline is particularly important in this age group. In order to account for this clinical need, we have launched this Special Issue, which will aim to highlight the progression of cognitive decline in older adults with Parkinson’s disease. We therefore welcome studies specifically focussing on older adults and associated cognitive change in the disorder.

Dr. Alison Yarnall
Dr. Rachael Lawson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Parkinson’s disease
  • dementia
  • mild cognitive impairment
  • ageing

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1141 KiB  
Article
Progression of Neuropsychiatric Symptoms over Time in an Incident Parkinson’s Disease Cohort (ICICLE-PD)
by J. K. Dlay, G. W. Duncan, T. K. Khoo, C. H. Williams-Gray, D. P. Breen, R. A. Barker, D. J. Burn, R. A. Lawson and A. J. Yarnall
Brain Sci. 2020, 10(2), 78; https://doi.org/10.3390/brainsci10020078 - 02 Feb 2020
Cited by 18 | Viewed by 3325
Abstract
Background: Cross-sectional studies have identified that the prevalence of neuropsychiatric symptoms (NPS) in Parkinson’s disease (PD) ranges from 70–89%. However, there are few longitudinal studies determining the impact of NPS on quality of life (QoL) in PD patients and their caregivers. We seek [...] Read more.
Background: Cross-sectional studies have identified that the prevalence of neuropsychiatric symptoms (NPS) in Parkinson’s disease (PD) ranges from 70–89%. However, there are few longitudinal studies determining the impact of NPS on quality of life (QoL) in PD patients and their caregivers. We seek to determine the progression of NPS in early PD. Methods: Newly diagnosed idiopathic PD cases (n = 212) and age-matched controls (n = 99) were recruited into a longitudinal study. NPS were assessed using the Neuropsychiatric Inventory with Caregiver Distress scale (NPI-D). Further neuropsychological and clinical assessments were completed by participants, with reassessment at 18 and 36 months. Linear mixed-effects modelling determined factors associated with NPI-D and QoL over 36 months. Results: Depression, anxiety, apathy and hallucinations were more frequent in PD than controls at all time points (p < 0.05). Higher motor severity at baseline was associated with worsening NPI-D scores over time (β = 0.1, p < 0.05), but not cognition. A higher NPI total score was associated with poorer QoL at any time point (β = 0.3, p < 0.001), but not changed in QoL scores. Conclusion: NPS are significantly associated with poorer QoL, even in early PD. Screening for NPS from diagnosis may allow efficient delivery of better support and treatment to patients and their families. Full article
(This article belongs to the Special Issue Progression of Cognitive Decline in Older Adults with Parkinson’s)
►▼ Show Figures

Figure 1

11 pages, 482 KiB  
Article
Cognitive Impairments and Self-Reported Sleep in Early-Stage Parkinson’s Disease with Versus without Probable REM Sleep Behavior Disorder
by Jonathan Trout, Taylor Christiansen, M. Brooks Bulkley, Jared J. Tanner, Christopher N. Sozda, Dawn Bowers and Daniel B. Kay
Brain Sci. 2020, 10(1), 9; https://doi.org/10.3390/brainsci10010009 - 21 Dec 2019
Cited by 12 | Viewed by 3161
Abstract
Parkinson’s disease (PD) is associated with cognitive and sleep impairments. The presence of rapid eye movement (REM) sleep behavior disorder (RBD) symptoms may represent a worse disease prognosis for PD individuals. We investigated cognitive functioning and self-reported sleep in early-stage PD individuals with [...] Read more.
Parkinson’s disease (PD) is associated with cognitive and sleep impairments. The presence of rapid eye movement (REM) sleep behavior disorder (RBD) symptoms may represent a worse disease prognosis for PD individuals. We investigated cognitive functioning and self-reported sleep in early-stage PD individuals with (n = 19) or without (n = 31) probable RBD. Probable RBD was defined as >5 on the REM Sleep Behavior Disorder Screening Questionnaire. Inhibition, visuospatial cognitive abilities, working memory, sustained visual attention, verbal fluency, and episodic memory were assessed. Sleep impairments were assessed using the Pittsburgh Sleep Quality Index, Insomnia Severity Index, Epworth Sleepiness Scale, and Patient-Reported Outcomes Measurement Information System questionnaires. Chi-squared, Mann-Whitney U, and independent sample t-tests were employed to assess group differences. Participants with PD and probable RBD performed significantly worse on word reading and switching verbal fluency tasks than PD participants without probable RBD (p < 0.05). No significant differences were found in mood, PD severity, or sleep measures between PD individuals with or without probable RBD. Cognitive tasks that involve verbal or switching components may be most impaired in PD individuals with probable RBD. Larger samples are needed to determine whether other cognitive domains and sleep features are significantly associated with RBD in PD. Full article
(This article belongs to the Special Issue Progression of Cognitive Decline in Older Adults with Parkinson’s)
►▼ Show Figures

Figure 1

11 pages, 265 KiB  
Article
Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
by Gloria Martí-Andrés, Rayco Jiménez-Bolaños, José Matias Arbelo-González, Javier Pagonabarraga, Carmen Duran-Herrera, Rafael Valenti-Azcarate and Mª Rosario Luquin
Brain Sci. 2019, 9(10), 272; https://doi.org/10.3390/brainsci9100272 - 11 Oct 2019
Cited by 14 | Viewed by 3495
Abstract
Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). Methods: A retrospective multicenter cohort study was conducted, in which the clinical effect of safinamide on both motor [...] Read more.
Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). Methods: A retrospective multicenter cohort study was conducted, in which the clinical effect of safinamide on both motor and NMS was assessed by the Clinical Global Impression of Change scale. Furthermore, we assessed the appearance of adverse events (AEs) and its effect on dyskinesia, that were also recorded in non-fluctuating PD patients and in those previously treated with rasagiline. Results: We included 213 PD patients who received safinamide in addition to their regular levodopa therapy. Thirty-five withdrew prematurely from safinamide, mainly because of AEs. Out of 178, clinical improvement on motor and NMS was found in 76.4% and 26.2%, respectively. A total of 44 reported AEs of mild intensity. We did not find a difference concerning the clinical benefit or AEs when comparing either patients who had or had not been taking Monoamine Oxidase B Inhibitor (MAOB-I) previously or between patients with and without motor complications. Conclusions: Safinamide is an effective and safe add-on to levodopa drug for PD patients. Moreover, safinamide could elicit an additional clinical improvement in PD patients previously treated with other MAOB-I and in non- fluctuating patients with suboptimal motor control. Full article
(This article belongs to the Special Issue Progression of Cognitive Decline in Older Adults with Parkinson’s)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop